Alpha Cognition Inc. (ACOG) Price to Earnings Ratio
High patent barriers and stringent FDA safety requirements provide significant protection for Alpha Cognition (ACOG) developments in the field of cognitive disorders. The accuracy of therapy data is guaranteed by strict controls during the transport of biomaterials. This chart on GURU.Markets shows that the P/E ratio is -8.10. The business model relies on R&D and production outsourcing, fully delegating drug manufacturing to external contractors.
Analytical breakdowns for Alpha Cognition Inc (ACOG)
- price and consensus price forecast:
- market capitalization details:
- book capitalization information:
- company liabilities and liquidity data:
Total Debt to Capital Alpha Cognition|ACOG - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Alpha Cognition Corp|ACOG - Company Aggregate Debts|Debt to Book Value Alpha Cognition Inc.|ACOG - Company Long-Term Debt|Short-Term Debt Alpha Cognition|Critical Liquidity alphacognition.com
- net income and valuation multiples indicators:
ACOG - Company Net Income|Net Profit Forecast Alpha Cognition|ACOG - P/E Multiple|Market Cap to Projected Earnings Alpha Cognition Corp|ACOG - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Alpha Cognition Inc.|ACOG - Operating profit EBITDA|Net earnings per share for the last four quarters Alpha Cognition|ACOG - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months alphacognition.com|ACOG - Earnings per share growth in current year|Projected earnings per share growth rate for next year Alpha Cognition
Summary company analysis:ACOG alphacognition.com
For Alpha Cognition, a developer of Alzheimer's disease therapies, the P/E ratio serves as an indicator of market expectations regarding future earnings. This metric is calculated as the ratio of market capitalization to net income, determining the cost of one dollar of earnings. By analyzing the price-to-earnings trend, an investor assesses the degree of the asset's overvaluation. In this instance, the indicator reflects the market's speculative bet on the successful FDA approval of the Alpha-1062 molecule.
Analysis of competing companies
P/E Multiple biogen.com|Price to Earnings Ratio Neurocrine Biosciences, Inc. (NBIX)|Price to Earnings Ratio RGC (Regencell Bioscience Ltd)|Price to Earnings Ratio Axsome Therapeutics Inc AXSM|ACAD (ACADIA Corp) - Market Cap to Net Income|Xenon Pharmaceuticals - P/E Multiple|Company Value to Net Income VKTX (vikingtherapeutics.com)|SUPN: P/E Multiple|Catalyst Pharma (CPRX) - P/E Multiple|Price to Earnings Ratio DNLI|HRMY: Company Value to Net Income|P/E Multiple BHVN|Price to Earnings Ratio amylyx.com AMLX|Price to Earnings Ratio Trevi Therapeutics, Inc. TRVI|Praxis Precision Medicines Inc (PRAX) - Market Cap to Earnings|Anavex Corp - P/E Multiple|Market Cap to Net Income Ratio CeriBell EEG (CBLL)|prothena.com (PRTA) - Price to Earnings Ratio|Price to Earnings Multiple ALEC|ANNX (Annexon) - P/E Multiple|Omeros Corp. (OMER) - Business Payback Period|Price to Earnings Ratio NGNE (Neurogene Corp)|Market Price to Net Income Ratio ACIU|P/E Multiple VYGR (Voyager Therapeutics)|Business Payback Period neumoratx.com (NMRA)|SCLX - Price to Earnings Ratio|Market Cap to Earnings Tevogen Bio Holdings Inc.|Cognition Therapeutics, Inc. (CGTX) - Price to Earnings Ratio|Price to Earnings Multiple IKT|SAVA (Cassava Sciences, Inc.) - P/E Multiple|P/E Multiple Assertio Therapeutics|P/E Multiple COYA|Price to Earnings Ratio vistagen.com VTGN|Price to Earnings Ratio Ovid Therapeutics OVID|Acumen Pharmaceuticals, Inc (ABOS) - Market Cap to Earnings|CervoMed Inc. - P/E Multiple|Market Cap to Net Income Ratio Alterity Therapeutics (ATHE)|clene.com (CLNN) - Price to Earnings Ratio|Price to Earnings Multiple PEPG|JUNS (Jupiter Neurosciences) - P/E Multiple|Market Cap to Earnings Relmada Corp RLMD|Price to Earnings Ratio ANVS (Annovis Bio, Inc.)|P/E Multiple gracetx.com (GRCE)|Price to Earnings Ratio Firefly Neuroscience AIFF|Company Value to Net Income KLTO|NRSN - Price to Earnings Ratio|Market Cap to Earnings Reviva Pharmaceuticals, Inc.|MTVA: P/E Multiple|neuraxis.com (NRXS) - P/E Multiple|Price to Earnings Ratio Helius Medical Technologies, Inc.|Price to Earnings Ratio PASG|Price to Earnings Ratio Neuphoria Therapeutics Inc. (NEUP)|NERV: Market Cap to Net Income|P/E Multiple ATHA (Athira Pharma, Inc.)|Company Value to Net Income ADXN|Alzamend - P/E Multiple|CYCN - P/E Multiple|PTIX (protagenic.com) - Price to Earnings Ratio|Pasithea Therapeutics Corp. - Company Value to Net Income|CRGT (Cortigent Inc) - P/E Multiple|Price to Earnings Ratio avenuetx.com (ATXI)|Price to Earnings Ratio BrainStorm Cell Therapeutics (BCLI)|CARA - Market Cap to Earnings|P/E Multiple CHRO (Chromocell Therapeutics Corporation)|Market Cap to Net Income Ratio Eliem Therapeutics, Inc.|ITCI - Price to Earnings Ratio|LBPH (longboardpharma.com) - Price to Earnings Multiple|MRNS: P/E Multiple|NKGN - Business Payback Period|Price to Earnings Ratio NRBO|SAGE (Sage Therapeutics Inc) - Market Price to Net Income Ratio|P/E Multiple SNPX|Business Payback Period trevena.com|Price to Earnings Ratio Vigil Neuroscience, Inc. VIGL|anewmeds.com (WENA) - Market Cap to Earnings|CERE - Price to Earnings Ratio
